Almirall to focus on respiratory and skin diseases
Catalan Economy
01 Jan 2010
Pharmaceutical group almirall is to focus its r+d investments on new treatments for respiratory diseases such as asthma and chronic obstructive pulmonary disease (copd) and skin problems, particularly psoriasis and skin cancer.
according to almirall's development director pere berga, the company invested nearly eur 100 million in r&d in 2009. the lab also expects to finalize this year clinical trials for eklira, its new drug for copd. in 2009, almirall posted eur 701 million in revenue, with net profit reaching eur 141 million. the group has a team of 550 researchers at its three centers in sant feliu de llobregat, sant just desvern and sant andreu de la barca (barcelona).
source: expansión 25/01/2010
Related news and success stories.
-
27 Mar 2024
Catalonia presents the success of its economic cluster policy at Harvard University
-
26 Mar 2024
The children's product sector in Catalonia has a turnover of over €4.4 billion
-
14 Mar 2024
Catalunya Meetings & Sports initiative boosts sports tourism in Catalonia
-
07 Mar 2024
Catalonia Trade & Investment attracts 880 million euros in foreign investment in 2023, the highest figure on record